Literature DB >> 36101542

Filamin A Variant as a Possible Second-Hit Gene Promoting Moyamoya Disease-like Vascular Formation Associated With RNF213 p.R4810K Variant.

Yasuhito Ikeuchi1, Jiro Kitayama1, Noriyuki Sahara1, Takuya Okata1, Noriko Miyake1, Naomichi Matsumoto1, Takanari Kitazono1, Tetsuro Ago1.   

Abstract

Background and Objective: The objective of this case report was to identify a second-hit gene that may promote Moyamoya disease (MMD)-like vascular formation in an individual having the RNF213 p.R4810K variant.
Methods: We performed magnetic resonance imaging and genetic analyses of RNF213 and FLNA in a 21-year-old woman, who showed Ehlers-Danlos-like symptoms and developed a first-ever unprovoked seizure, and of her healthy parents.
Results: We identified bilateral periventricular nodular heterotopia (PNH) as the cause of seizures and MMD-like vascular formation in the patient. The patient had the RNF213 p.R4810K variant. Exome analysis identified c.4868delG in the X-linked FLNA gene encoding filamin A p.G1623V fs*41, which could explain PNH and Ehlers-Danlos-like symptoms. Her mother had the same FLNA variant and had asymptomatic bilateral PNH, whereas her father had the RNF213 variant and had normal cerebrovascular structure. Discussion: The family study suggested that the FLNA variant promoted MMD-like vascular formation in a patient having the RNF213 variant, while the RNF213 variant amplified the phenotypic changes elicited by the FLNA abnormality. Collectively, we identified a gene abnormality in filamin A, a target of RNF213-mediated proteasomal degradation, that may promote MMD-like vascular formation as a possible second-hit gene in individuals having the RNF213 p.R4810K variant.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Entities:  

Year:  2022        PMID: 36101542      PMCID: PMC9465836          DOI: 10.1212/NXG.0000000000200017

Source DB:  PubMed          Journal:  Neurol Genet        ISSN: 2376-7839


Moyamoya disease (MMD) is characterized by chronic stenosis or occlusion of the terminal portion of the internal carotid artery accompanied by the formation of abnormal vascular networks. Its familial and regional prevalence in East Asia suggests genetic involvement: A genome-wide association study identified the RNF213 (NM_001256071.3) c.14429G>A (p.R4810K) variant as a susceptible gene for MMD.[1] This variant is found in 80% of patients with MMD in Japan, whereas 1.8% of healthy controls have this variant.[2] Because MMD develops in approximately 1 per 10,000 Japanese individuals, it can be estimated that 1%–2% of patients having the variant would develop MMD. However, recent reports have demonstrated that the RNF213 variant is frequently identified in stroke and nonstroke patients with large-artery atherosclerosis, thereby expanding its impact beyond MMD.[2] Experiments in mice with genetic deletion of Rnf213 or carrying human RNF213 c.14429G>A knock-in did not show any abnormal cerebrovascular structures. Therefore, it is believed that additional genetic or environmental factors are required to develop MMD in individuals having RNF213 p.R4810K variant, that is, the two-hit theory in MMD.[3]

Case Description

A 21-year-old woman developed generalized tonic-clonic seizures when she visited our hospital due to headaches and transient loss of consciousness. IV administration of diazepam easily controlled seizures. She had no mental retardation or known CNS disorders except depression and migraine. We observed joint hypermobility (Figure 1) and ecchymoma in her lower limbs, with a medical history of patellar luxation and spontaneous pneumothorax. MRI revealed bilateral periventricular nodular heterotopia (PNH) (Figure 1). Magnetic resonance angiography (MRA) revealed stenosis of the terminal portion of the bilateral internal carotid artery and MMD-like abnormal vascular networks (Figure 1). Transthoracic echocardiography revealed mild aortic regurgitation. Bilateral PNH accompanied by Ehlers-Danlos–like symptoms resembled the variant phenotype of the X-linked gene FLNA (NM_001456.4), encoding filamin A.[4] An exome analysis of the patient identified a previously unknown heterozygous variant in FLNA (c.4868delG), creating a protein with Gly1623Val substitution with early termination, omitting the C-terminal 983 amino acids (p.G1623V fs*41) (Figure 2). We also sequenced RNF213 and found the heterozygous c.14429G>A variant (Figure 2). We further performed brain MRI/MRA and genetic analyses in the patient's parents. Her mother had the same FLNA variant, but not the RNF213 variant, with asymptomatic bilateral PNH and normal cerebrovascular structure (Figures 1 and 2). By contrast, her father did not show any abnormalities on MRI and MRA while having the heterozygous RNF213 variant (Figures 1 and 2).
Figure 1

Pedigree and Neuroimaging

(Patient) Bilateral PNH (yellow arrows) on T2-weighted images and narrowing of the bilateral internal carotid artery terminal portion accompanied by MMD-like vascular formation on MRA. Hypermobility of the thumb is shown. (Mother) Asymptomatic bilateral PNH (yellow arrows) without MMD-like vascular formation and Ehlers-Danlos–like symptoms. (Father) No abnormalities on MRI/MRA. MMD = Moyamoya disease; MRA = magnetic resonance angiography; PNH = periventricular nodular heterotopia.

Figure 2

Sequencing of RNF213 and FLNA

(A) A single nucleotide substitution of G to A at 14429 in the RNF213 gene (c.14429G>A, p.Arg4810Lys) is identified in the patient and her father. (B) A single nucleotide deletion at 4868 in the FLNA gene (c.4868delG), leading to p.Gly1623Val fs*41 is identified in the patient and her mother. Fw = forward; Rv = reverse.

Pedigree and Neuroimaging

(Patient) Bilateral PNH (yellow arrows) on T2-weighted images and narrowing of the bilateral internal carotid artery terminal portion accompanied by MMD-like vascular formation on MRA. Hypermobility of the thumb is shown. (Mother) Asymptomatic bilateral PNH (yellow arrows) without MMD-like vascular formation and Ehlers-Danlos–like symptoms. (Father) No abnormalities on MRI/MRA. MMD = Moyamoya disease; MRA = magnetic resonance angiography; PNH = periventricular nodular heterotopia.

Sequencing of RNF213 and FLNA

(A) A single nucleotide substitution of G to A at 14429 in the RNF213 gene (c.14429G>A, p.Arg4810Lys) is identified in the patient and her father. (B) A single nucleotide deletion at 4868 in the FLNA gene (c.4868delG), leading to p.Gly1623Val fs*41 is identified in the patient and her mother. Fw = forward; Rv = reverse.

Discussion

In this study, we clearly demonstrated that the patient inherited the RNF213 variant from her father and the FLNA variant from her mother (Figures 1 and 2). Because only the patient having the 2 variants manifested symptomatic PNH accompanied by Ehlers-Danlos–like symptoms and MMD-like vascular formation, each gene abnormality alone may cause only subtle phenotypic changes while their coexistence may mutually amplify them. It is important that the direct interaction between the 2 molecules is known: Filamin A undergoes RNF213-mediated ubiquitination and proteasomal degradation for its turnover.[2] Because ligase activity of RNF213 p.R4810K is decreased, the abnormal filamin A may accumulate in cells expressing RNF213 and filamin A.[2] Filamin A regulates cellular mobility through its dimerization and interaction with various molecules, including integrin, via its C-terminal portion, which further interacts with extracellular matrix proteins, while the N-terminal portion participates in actin-binding and ubiquitination (Figure 3).[4] The C-terminally truncated filamin A may impair the migration of newborn neurons from the periventricular zone to the cortex during development, resulting in PNH. In adults, the filamin A variant may cause flow-mediated or pressure-mediated hypermobility of vascular smooth muscle cells, resulting in increased calcium influx through the mechanosensor channel, thereby inducing arterial remodeling and stenosis of cerebral arteries (Figure 3).[5]
Figure 3

Putative Mechanism Underlying Hypermobility of Vascular Smooth Muscle Cells Leading to Arterial Remodeling in the Patient Having RNF213 p.R4810K and FLNA p.G1623V fs*41

(A) Filamin A forms a homodimer and interacts directly with integrin via its C-terminal portion, while its N-terminal portion interacts with filamentous actin (F-actin) and undergoes RNF213-mediated ubiquitination for its turnover. Integrin interacts with ECM, thereby preventing hypermobilization of vascular smooth muscle cells. (B) The filamin A variant with p.G1623V fs*41, which lacks its C-terminal portion, can neither form a homodimer nor interact with integrin, thereby causing hypermobilization of vascular smooth muscle cells. The hypermobilization of the cells increases the calcium influx through the mechanosensor channel Piezo1 that leads to arterial remodeling. Because the RNF213 p.R4810K variant has a decreased ubiquitin ligase activity that is required for the degradation and turnover of filamin A, the filamin A variant would accumulate and amplify its phenotypic changes as a dominant-negative form in the cells expressing the RNF213 p.R4810K variant. ECM = extracellular matrix proteins.

Putative Mechanism Underlying Hypermobility of Vascular Smooth Muscle Cells Leading to Arterial Remodeling in the Patient Having RNF213 p.R4810K and FLNA p.G1623V fs*41

(A) Filamin A forms a homodimer and interacts directly with integrin via its C-terminal portion, while its N-terminal portion interacts with filamentous actin (F-actin) and undergoes RNF213-mediated ubiquitination for its turnover. Integrin interacts with ECM, thereby preventing hypermobilization of vascular smooth muscle cells. (B) The filamin A variant with p.G1623V fs*41, which lacks its C-terminal portion, can neither form a homodimer nor interact with integrin, thereby causing hypermobilization of vascular smooth muscle cells. The hypermobilization of the cells increases the calcium influx through the mechanosensor channel Piezo1 that leads to arterial remodeling. Because the RNF213 p.R4810K variant has a decreased ubiquitin ligase activity that is required for the degradation and turnover of filamin A, the filamin A variant would accumulate and amplify its phenotypic changes as a dominant-negative form in the cells expressing the RNF213 p.R4810K variant. ECM = extracellular matrix proteins. We cannot completely exclude that the FLNA abnormality coexists independently of MMD in the patient. Even if it is related to MMD, it may be uncommon in MMD. There has been 1 case series that briefly described a 3-year-old male patient having an FLNA abnormality among 54 patients with MMD.[6] Although FLNA variants presenting with PNH often show X-linked dominant inheritance, we should note that some FLNA variants are transmitted in X-linked recessive mode and their phenotypic changes may be affected by X-inactivation.[7] Collectively, we identify FLNA as a possible second-hit gene that may affect MMD-like vascular formation in an individual having the RNF213 p.R4810K variant. RNF213 also functions as an E3-ubiquitin ligase for itself and other molecules, including NFAT.[2] Moreover, RNF213 contributes to lipid metabolism.[2] Thus, besides FLNA, there may be other RNF213-related genes whose abnormality can elicit MMD-like vascular formation associated with the RNF213 p.R4810K variant.
  7 in total

1.  A genome-wide association study identifies RNF213 as the first Moyamoya disease gene.

Authors:  Fumiaki Kamada; Yoko Aoki; Ayumi Narisawa; Yu Abe; Shoko Komatsuzaki; Atsuo Kikuchi; Junko Kanno; Tetsuya Niihori; Masao Ono; Naoto Ishii; Yuji Owada; Miki Fujimura; Yoichi Mashimo; Yoichi Suzuki; Akira Hata; Shigeru Tsuchiya; Teiji Tominaga; Yoichi Matsubara; Shigeo Kure
Journal:  J Hum Genet       Date:  2010-11-04       Impact factor: 3.172

Review 2.  The many faces of filamin: a versatile molecular scaffold for cell motility and signalling.

Authors:  Yuanyi Feng; Christopher A Walsh
Journal:  Nat Cell Biol       Date:  2004-11       Impact factor: 28.824

3.  Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy.

Authors:  Florence Kyndt; Jean-Pierre Gueffet; Vincent Probst; Philippe Jaafar; Antoine Legendre; Françoise Le Bouffant; Claire Toquet; Estelle Roy; Lesley McGregor; Sally Ann Lynch; Ruth Newbury-Ecob; Vinh Tran; Ian Young; Jean-Noel Trochu; Hervé Le Marec; Jean-Jacques Schott
Journal:  Circulation       Date:  2006-12-26       Impact factor: 29.690

4.  Factors associated with the presentation of moyamoya in childhood.

Authors:  Catherine Amlie-Lefond; Richard G Ellenbogen
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-04-10       Impact factor: 2.136

5.  Piezo1 in Smooth Muscle Cells Is Involved in Hypertension-Dependent Arterial Remodeling.

Authors:  Kevin Retailleau; Fabrice Duprat; Malika Arhatte; Sanjeev Sumant Ranade; Rémi Peyronnet; Joana Raquel Martins; Martine Jodar; Céline Moro; Stefan Offermanns; Yuanyi Feng; Sophie Demolombe; Amanda Patel; Eric Honoré
Journal:  Cell Rep       Date:  2015-10-29       Impact factor: 9.423

Review 6.  Genetics and Biomarkers of Moyamoya Disease: Significance of RNF213 as a Susceptibility Gene.

Authors:  Miki Fujimura; Shinya Sonobe; Yasuo Nishijima; Kuniyasu Niizuma; Hiroyuki Sakata; Shigeo Kure; Teiji Tominaga
Journal:  J Stroke       Date:  2014-05-30       Impact factor: 6.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.